|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We studied global gene expression in three melanoma cell lines with the most common and potent V600E mutation in the B-RAF gene-four cell lines with a common Q61R mutation in the N-RAS gene and three cell lines with no mutations using human HG-U133A 2.0 micro-arrays with 22 277 transcripts.
|
15760917 |
2005 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
23569304 |
2013 |
|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
|
23538902 |
2013 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
NRAS-mutant melanoma: response to chemotherapy.
|
21576590 |
2011 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
|
23538902 |
2013 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions.
|
20149136 |
2010 |
|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The rarity of HRAS and KRAS Q61R mutants in malignant melanoma</span> let previous investigations erroneously conclude that SP174 is specific for NRAS Q61R-mutant protein.
|
29206715 |
2018 |
|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma.
|
30651601 |
2019 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
NRAS-mutant melanoma: response to chemotherapy.
|
21576590 |
2011 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
|
22761467 |
2012 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
|
22761467 |
2012 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
|
22761467 |
2012 |
|
rs11554290
|
|
melanoma
|
G |
0.800 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs11554290
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutation in BRAF and NRAS was present in 43% (88% V600E, 10% V600K) and 30% (48% Q61K, 40% Q61R) of metastatic melanomas, respectively.
|
23855428 |
2013 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
|
23538902 |
2013 |
|
rs11554290
|
|
melanoma
|
C |
0.800 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs11554290
|
|
melanoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
|
20406486 |
2010 |